Outstanding Support: The vendors professional support team is highly knowledgeable about peptides and is sure to address all concerns as quickly as possible
Daily dosing is the standard for oral NAD+ supplements
It does not make eating less feel easier, does not reduce cravings, and does not change food preferences
How Tirzepatide Works Mimics GLP-1 and GIP hormones to improve insulin response Reduces appetite and food intake Slows gastric emptying, increasing feelings of fullness Helps regulate blood sugar while promoting weight loss Benefits of Tirzepatide Significant weight loss reported in clinical trials, sometimes over 20% of body weight Improves blood sugar control for people with diabetes or prediabetes Reduces risk factors related to obesity such as high blood pressure and cholesterol Administered once weekly via injection, convenient dosing Limitations and Considerations Possible side effects include nausea, diarrhea, and vomiting, especially early in treatment Prescription medication requiring medical supervision Not suitable for people with certain medical conditions Cost and insurance coverage may be limiting factors Comparing AOD 9604 and Tirzepatide | Feature | AOD 9604 | Tirzepatide | |------------------------|---------------------------------|--------------------------------| | Origin | Peptide fragment of growth hormone | Synthetic dual hormone agonist | | Primary use | Fat metabolism and weight management | Type 2 diabetes and weight loss | | Mechanism | Stimulates fat breakdown, inhibits fat creation | Regulates appetite and insulin | | Administration | Injection or nasal spray (varies) | Weekly injection | | Weight loss potential | Moderate, supports fat loss | High, up to 20%+ body weight | | Side effects | Minimal, mostly mild | Gastrointestinal symptoms common| | Approval status | Limited regulatory approval | FDA approved for diabetes and weight loss | | Cost | Generally lower | Higher, prescription required | Who Should Consider AOD 9604
[DOI] [PMC free article] [PubMed] [Google Scholar] 205.Farhan SM, Robinson JF, McIntyre AD, Marrosu MG, Ticca AF, Loddo S, et al
